Phase 1 clinical trial of poliovirus therapy shows long-term survival benefit for rec
 

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial.

More...